Tandem Diabetes (TNDM) Tops Q4 EPS by 22c, Revenues Beat; Offers FY19 Revenue Guidance Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Tandem Diabetes Care Reports 2018 Financial Results and 2019 Financial Guidance
February 26, 2019 4:05 PM ESTSAN DIEGO--(BUSINESS WIRE)-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today reported its financial results for the quarter and year ended December 31, 2018 and financial guidance for the year ending December 31, 2019.
In comparing the fourth quarter of 2018 to the same period of 2017:
Pump shipments increased 133 percent to 16,168 pumps from 6,950 pumps Sales increased 89 percent to $76.2 million from $40.3 million Operating margin improved to 1 percent from negative 24 percentIn comparing the year ended December 31, 2018 to the same period of 2017:
... More